Skip to main content
T&R Biofab Co., Ltd logo

T&R Biofab Co., Ltd — Investor Relations & Filings

Ticker · 246710 ISIN · KR7246710008 KO Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2023-03-13 AGM Information
Country KR South Korea
Listing KO 246710

About T&R Biofab Co., Ltd

http://www.tnrbiofab.com/en/

T&R Biofab Co., Ltd. is a biomedical engineering company specializing in the development and commercialization of regenerative medical technologies. The company utilizes its proprietary 3D bioprinting technology to manufacture a range of products. Its primary offerings include 3D-printed, bioresorbable medical scaffolds designed to aid in the regeneration and reconstruction of tissues and organs. Other key business areas encompass bio-surgical solutions, the development of organoids and mini-tissues for research and therapeutic applications, and the use of human induced pluripotent stem cells (hiPSC).

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for the 10th Annual General Meeting of TNR Biofab. It contains the meeting agenda, financial statements (balance sheet, income statement, cash flow statement), and management's business outlook. While it contains financial data, it is primarily a proxy statement/notice sent to shareholders to inform them of the upcoming meeting and request their participation/votes. According to the filing definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category, as it provides information and requests votes for the meeting.
2023-03-13 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for T&R Biofab. It outlines the date, location, and agenda items (such as financial statement approval, stock option grants, and director compensation limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2023-03-10 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a correction (정정신고) to a previous filing. It details changes to stock option grants, including exercise prices and quantities, following a bonus issue. This type of disclosure regarding capital structure and equity-based compensation is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (which is for individual director trades) or SHA (which is for general share issuance).
2023-03-10 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (T&R Biofab) regarding a correction to a previously submitted financial disclosure ('매출액 또는 손익구조 30%이상 변동'). It details changes in revenue, operating profit, and net income due to audit adjustments. Since this is a specific regulatory announcement regarding financial performance updates and corrections, it falls under the 'RNS' (Regulatory Filings) category as it is a standard corporate disclosure filing in the Korean market. FY 2022
2023-03-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (T&R Biofab) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. It provides a summary table of financial performance and reasons for the variance, which fits the definition of a general regulatory filing (RNS) as it is a specific disclosure of financial events rather than a full annual report or a simple announcement of a report's publication. FY 2022
2023-02-13 Korean
파생상품거래손실발생
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from a Korean company (T&R Biofab) regarding a 'Loss from Derivatives Transaction'. It details the nature of the loss (valuation loss on convertible preferred shares and convertible bonds), the financial impact relative to equity, and the cause (K-IFRS accounting requirements). Since this is a specific regulatory disclosure of a financial event that does not fit into standard periodic reports, dividend notices, or management changes, it falls under the general regulatory filing category.
2023-02-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.